Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]

被引：0
|
作者：
Chiarion-Sileni, V.
Guida, M.
Romanini, A.
Ridolfi, R.
Mandala, M.
Del Bianco, P.
Silvestri, B.
Medici, M.
Michiara, M.
Dalla Palma, M.
Puccetti, O.
Pigozzo, J.
Laveder, F.
De Salvo, G. L.
机构：
[1] IOV IRCCS, Ist Oncol Veneto, Med Oncol Unit, Padua, Italy
[2] Ist Oncol, Bari, Italy
[3] Santa Chiara Univ Hosp Pisa, Pisa, Italy
[4] IRST, Immuntherapy Unit, Meldola, Italy
[5] Hosp Bergamo, Bergamo, Italy
[6] Clin Trials & Biostat Unit, Padua, Italy
[7] Gen Hosp, Noale, Italy
[8] Osped Angelo, Mestre Venice, Italy
[9] Gen Hosp, Parma, Italy
[10] Osped San Bortolo, Vicenza, Italy
[11] Osped Civile, Thiene, Italy
[12] Osped Civile, Belluno, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8506
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients
    Weichenthal, Michael
    Chiarion-Sileni, Vanna
    Hauschild, Axel
    Del Bianco, Paola
    Trefzer, Uwe
    Guida, Michele
    Enk, Alexander
    Romanini, Antonella
    Loquai, Carmen
    Ridolfi, Ruggero
    Schadendorf, Dirk
    Mandala, Mario
    Koller, Josef
    Silvestri, Barbara
    Gogas, Helen
    Medici, Michele
    Dummer, Reinhard
    De Salvo, Gian Luca
    Mohr, Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: An interim analysis of a randomized phase III study (NCT00226408)
    Mohr, P.
    Hauschild, A.
    Enk, A.
    Trefzer, U.
    Rass, K.
    Grabbe, S.
    Brockmeyer, N. H.
    Koller, J.
    Gogas, H.
    Weichenthal, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI-Mel.A.) [ISRCTN75125874]
    Chiarion-Sileni, V
    Del Bianco, P
    Romanini, A
    Guida, M
    Paccagnella, A
    Dalla Palma, M
    Naglieri, E
    Ridolfi, R
    Silvestri, B
    Michiara, M
    De Salvo, GL
    [J]. BMC CANCER, 2006, 6 (1)
  • [4] Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
    Vanna Chiarion-Sileni
    Paola Del Bianco
    Antonella Romanini
    Michele Guida
    Adriano Paccagnella
    Maurizio Dalla Palma
    Emanuele Naglieri
    Ruggero Ridolfi
    Barbara Silvestri
    Maria Michiara
    Gian Luca De Salvo
    [J]. BMC Cancer, 6
  • [5] Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408).
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Enk, Alexander
    Tilgen, Wolfgang
    Loquai, Carmen
    Gogas, Helen
    Haalck, Thomas
    Koller, Josef
    Schadendorf, Dirk
    Dummer, Reinhard
    Gutzmer, Ralf
    Brockmeyer, Norbert
    Hoelzle, Erhard
    Sunderkoetter, Cord
    Mauch, Cornelia
    Stein, Anette
    Schneider, Lars
    Podda, Maurizio
    Weichenthal, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Quality-of-life (QoL) impairment in melanoma patients receiving high-dose interferon alpha 2b (IFNa2b)
    Mohr, P.
    Hauschild, A.
    Rass, K.
    Trefzer, U.
    Enk, A.
    Haalck, T.
    Koller, J.
    Gutzmer, R.
    Kuechler, T.
    Weichenthal, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Enk, Alexander
    Tilgen, Wolfgang
    Loquai, Carmen
    Gogas, Helen
    Haalck, Thomas
    Koller, Josef
    Dummer, Reinhard
    Gutzmer, Ralf
    Brockmeyer, Norbert
    Hoelzle, Erhard
    Sunderkoetter, Cord
    Mauch, Cornelia
    Stein, Annette
    Schneider, Lars A.
    Podda, Maurizio
    Goeppner, Daniela
    Schadendorf, Dirk
    Weichenthal, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4077 - +
  • [8] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    Kirkwood, John M.
    Tarhini, Ahmad A.
    Moschos, Stergios J.
    Panelli, Monica C.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 2 - 3
  • [9] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    John M Kirkwood
    Ahmad A Tarhini
    Stergios J Moschos
    Monica C Panelli
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 2 - 3
  • [10] A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma
    Grignol, Valerie P.
    Olencki, Thomas
    Relekar, Kiran
    Taylor, Cynthia
    Kibler, Amanda
    Kefauver, Cheryl
    Wei, Lai
    Walker, Michael J.
    Chen, Helen X.
    Kendra, Kari
    Carson, William E., III
    [J]. JOURNAL OF IMMUNOTHERAPY, 2011, 34 (06) : 509 - 515
12345